MYCOSIS FUNGOIDES
Clinical trials for MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells get a navigation system to hunt down lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has not responded to standard therapy or has returned. The treatment uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack c…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug shows promise for rare skin cancers
Disease control OngoingThis study tests a drug called brentuximab vedotin in 79 people with CD30-positive skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis). The goal is to see if the drug can shrink or control the skin tumors. Participants receive the drug every 3 weeks, and researche…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy for rare skin cancer shows promise in early trial
Disease control TerminatedThis study tests whether adding a targeted drug called mogamulizumab to standard light therapy works better for early-stage mycosis fungoides, a rare type of skin lymphoma. About 20 adults will receive both treatments together. The goal is to see how many patients' skin lesions i…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug shows promise for rare skin cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called tulmimetostat (DZR123) in 24 adults with advanced mycosis fungoides or Sezary syndrome, rare types of skin lymphoma. Participants must have already tried at least one prior treatment. The main goals are to check the drug's safety and…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Drug combo shows promise for rare skin cancer
Disease control OngoingThis study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can help control advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. It includes 14 adults who have already tried at least one other treatment. T…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC